Latest News about AVIR
Recent news which mentions AVIR
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US
September 26, 2022
Tickers
AVIR
From Benzinga
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir
September 13, 2022
Tickers
AVIR
From Benzinga
Tickers
AVIR
From Motley Fool
From Motley Fool
Tickers
AVIR
From Motley Fool
From Benzinga
5 Value Stocks In The Healthcare Sector
April 25, 2022
From Benzinga
30 Stocks Moving in Tuesday's Pre-Market Session
March 15, 2022
From Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
March 01, 2022
From Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 01, 2022
From Benzinga
27 Stocks Moving in Monday's Pre-Market Session
March 01, 2022
From Benzinga
Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript
February 28, 2022
Tickers
AVIR
From Motley Fool
From Motley Fool
Earnings Scheduled For February 28, 2022
February 28, 2022
From Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
January 06, 2022
From Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
January 06, 2022
From InvestorPlace
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
December 15, 2021
From Benzinga
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
December 15, 2021
From Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
November 18, 2021
From Benzinga
What 5 Analyst Ratings Have To Say About Atea Pharmaceuticals
November 18, 2021
Tickers
AVIR
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.